Business
Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference
STATEN ISLAND, N.Y., April 25, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical
About this update from Acurx Pharmaceuticals, Inc.
[{"type":"text","content":"STATEN ISLAND, N.Y., April 25, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (\"Acurx\" or the \"Company\"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that results from the ibezapolstat Phase 2 clinical trial in patients with C. difficile Infection (CDI) will be presented at the 34th Congress of ESCMID Global (European Society of Clinical Microbiology and Infectious Diseases) being held in Barcelona, Spain, April 27-30, 2024.\n\nKevin Garey, PharmD, FIDSA, MS, Professor and Chair, University of Houston College of Pharmacy, and the Principal Investigator for microbiology and microbiome aspects of the ibezapolstat clinical trial program and Acurx Scientific Advisory Board member will give an oral presentation entitled: A Phase 2, Randomized, Double-Blind Study of Ibezapolstat Compared with Vancomycin for the Treatment of Clostridioides difficile Infection. The presentation will include additional analyses of clinical and microbiological data. \nOral Presentation:Tuesday, April 30, 2024: 8:30amTitle: Efficacy and safety of ibezapolstat compared with vancomycin for the treatment of Clostridioides difficile infection - a phase 2, randomized, double-blind studyPresenter: Kevin Garey, PharmD, FIDSA' Professor and Chair, University of Houston College of PharmacyLocation: Hall H\nPoster Presentation:Sunday, April 28, 2024; 12:00pmPoster Title: Antibacterial activity of ibezapolstat against antimicrobial resistant clinical strains of Clostridioides difficile Presenter: Eugenie Dr. Eugenie Basseres, Research Scientist, University of Houston College of PharmacyLocation: Poster #P2327\nThe presentation and poster will be made available on the Acurx Pharmaceuticals website following their respective presentations at the conference. www.acurxpharma.com\nAbout ESCMID Global (formerly ECCMID)ESCMID (European Society of Clinical Microbiology and Infectious Diseases) Global conference is recognized as the largest international forum for presentations and discussions of research in the fields of clinical microbiology and infection for experts from academia, the clinical setting and the industry. ESCMID's yearly congress attracts over 14,000 participants. ECCMID offers a wide range of sessions including: keynotes, symposia, poster se...